業績

英語論文

  • A nodular lesion of the foot detected by 18F-FDG PET/CT in mycosis fungoides: a plantar wart.
    Fujita Y, Natsuga K, Manabe O, Hirata K, Shimizu H
    Clin Nucl Med 44: 244-245, 2019.
  • Disseminated erythematous papules and pustules: A Quiz.
    Fujita Y, Shiiya C, Inamura-Takashima Y, Nomura T, Shibaki A, Shimizu H
    Acta Derm Venereol 99: 123-124, 2019.
  • The significance of tumor cells-derived MFG-E8 in tumor growth of angiosarcoma.
    Fujiwara C, Motegi SI, Ohira A, Yamaguchi S, Sekiguchi A, Yasuda M, Nakamura H, Makiguchi T, Yokoo S, Hoshina D, Abe R, Takahashi K, Ishikawa O
    J Dermatol Sci 96: 18-25, 2019.
  • AAGAB Controls AP2 Adaptor Assembly in Clathrin-Mediated Endocytosis.
    Gulbranson DR, Crisman L, Lee M, Ouyang Y, Menasche BL, Demmitt BA, Wan C, Nomura T, Ye Y, Yu H, Shen J
    Dev Cell 50: 436-446.e5, 2019.
  • Glutathione and cysteines suppress cytotoxicity of gas phase of cigarette smoke by direct reacting with unsaturated carbonyl compounds in the gas phase.
    Higashi T, Elmeligy E, Mai Y, Noya Y, Terada K, Mazaki Y, Kuge Y, Miwa S
    Biochem Biophys Res Commun 509: 988-993, 2019.
  • Chemoradiotherapy could improve overall survival of patients with stage IV cutaneous squamous cell carcinoma: analysis of 34 cases.
    Hiura A, Yoshino K, Maeda T, Nagai K, Oaku S, Kato M, Fujisawa Y
    Br J Dermatol 180: 1557-1558, 2019.
  • Continued Chemotherapy After Concurrent Chemoradiotherapy Improves Treatment Outcomes for Unresectable Cutaneous Squamous Cell Carcinoma: An Analysis of 13 Cases.
    Hiura A, Yoshino K, Maeda T, Nagai K, Oaku S, Yamashita C, Kato M, Uehara J, Fujisawa Y
    Front Med (Lausanne) 6: 207, 2019.
  • Fc-binding proteins enhance autoantibody-induced BP180 depletion in pemphigoid.
    Iwata H, Kamaguchi M, Ujiie H, Ujiie I, Natsuga K, Nishie W, Shimizu H
    J Pathol 247: 371-380, 2019.
  • A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K, Nishie W, Beniko M, Shimizu H
    Front Immunol 10: 1439, 2019.
  • The Diagnosis and Blistering Mechanisms of Mucous Membrane Pemphigoid.
    Kamaguchi M, Iwata H
    Front Immunol 10: 34, 2019.
  • Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine.
    Kamaguchi M, Iwata H, Asaka T, Kitagawa Y, Shimizu H
    Oral Sci Int. 16: 106-109, 2019.
  • The identification of autoantigens in mucous membrane pemphigoid using immortalized oral mucosal keratinocytes.
    Kamaguchi M, Iwata H, Miyauchi T, Ujiie H, Ujiie I, Nomura T, Ohga N, Shimizu H, Kitagawa Y
    J Oral Pathol Med 48: 60-67, 2019.
  • The direct binding of collagen XVII and collagen IV is disrupted by pemphigoid autoantibodies.
    Kamaguchi M, Iwata H, Nishie W, Toyonaga E, Ujiie H, Natsuga K, Kitagawa Y, Shimizu H
    Lab Invest 99: 48-57, 2019.
  • A Case of Malignant Melanoma Arising in Nagashima-type Palmoplantar Keratosis.
    Katayama S, Nomura T, Takeda M, Miyauchi T, Suzuki S, Peh JT, Nohara T, Kitamura S, Hata H, Shimizu H
    Acta Derm Venereol 99: 1311-1312, 2019.
  • Single-agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease: a case series.
    Kato M, Yoshino K, Maeda T, Nagai K, Oaku S, Hiura A, Fujisawa Y
    Br J Dermatol 181: 831-832, 2019.
  • Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
    Kawaguchi Y, Shimauchi R, Nishibori N, Kawashima K, Oshitani S, Fujiya A, Shibata T, Ohashi N, Izumi K, Nishie W, Shimizu H, Arima H, Sobajima H
    J Diabetes Investig 10: 392-398, 2019.
  • Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma.
    Kawamura A, Kawamura T, Riddell M, Hikita T, Yanagi T, Umemura H, Nakayama M
    Cancer Sci 110: 1780-1789, 2019.
  • Evaluation of pazopanib cytotoxicity to normal vascular endothelial cells in vitro: A comment on Goto et al.
    Kitamura S, Yanagi T, Maeda T, Imafuku K, Hata H, Masuzawa M, Shimizu H
    J Dermatol 46: e341-e342, 2019.
  • Epidermolysis Bullosa Acquisita: The 2019 Update.
    Koga H, Prost-Squarcioni C, Iwata H, Jonkman MF, Ludwig RJ, Bieber K
    Front Med (Lausanne) 5: 362, 2019.
  • Multiple cutaneous reticulohistiocytomas after haematopoietic cell transplantation: contribution of donor- and host-derived cells.
    Kosumi H, Natsuga K, Watanabe M, Okada K, Shimizu H
    Br J Dermatol 180: 680-681, 2019.
  • Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
    Kurihara Y, Yamagami J, Funakoshi T, Ishii M, Miyamoto J, Fujio Y, Kakuta R, Tanikawa A, Aoyama Y, Iwatsuki K, Ishii N, Hashimoto T, Nishie W, Shimizu H, Kouyama K, Amagai M
    J Dermatol 46: 124-130, 2019.
  • Type 1 diabetes mellitus in a melanoma patient treated with adjuvant nivolumab therapy.
    Maeda T, Kitamura S, Yanagi T, Narahira A, Miyamoto K, Hata H, Cho K, Kameda H, Nakamura A, Shimizu H
    J Cutan Immunol Allergy 2: 176-177, 2019.
  • The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma.
    Maeda T, Yoshino K, Nagai K, Oaku S, Kato M, Hiura A, Hata H
    Acta Oncol 58: 379-381, 2019.
  • Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients.
    Maeda T, Yoshino K, Nagai K, Oaku S, Kato M, Hiura A, Hata H
    Br J Dermatol 180: 1230-1231, 2019.
  • Reply to “Early ambulation versus bedrest after skin grafting in extramammary Paget’s disease”.
    Maeda T, Yoshino K, Nagai K, Oaku S, Kato M, Hiura A, Hata H
    J Dermatol 46: e186, 2019.
  • Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.
    Maeda T, Yoshino K, Nagai K, Oaku S, Kato M, Hiura A, Hata H
    Eur J Cancer 115: 13-16, 2019.
  • Dynamics of neutrophil and C-reactive protein reflect the clinical course of pyrexia during combination therapy with dabrafenib and trametinib.
    Maeda T, Yoshino K, Yamashita C, Nagai K, Oaku S, Kato M, Hiura A, Uehara J, Fujisawa Y
    J Dermatol 46: 716-719, 2019.
  • Hypoxia accelerates the progression of angiosarcoma through the regulation of angiosarcoma cells and tumor microenvironment.
    Maeda-Otsuka S, Kajihara I, Tasaki Y, Yamada-Kanazawa S, Sakamoto R, Sawamura S, Masuzawa M, Masuzawa M, Amoh Y, Hoshina D, Abe R, Komohara Y, Ihn H
    J Dermatol Sci 93: 123-132, 2019.
  • Case of epidermolytic ichthyosis with impairment of pulmonary function and exacerbated skin manifestations in a late middle-aged adult.
    Maekawa A, Arase N, Tamai K, Nomura T, Kiyohara E, Wataya-Kaneda M, Arase H, Katayama I, Fujimoto M
    J Dermatol 46: e480-e482, 2019.
  • Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y, Nishie W, Izumi K, Shimizu H:
    Front Immunol 10: 1224, 2019.
  • Autoantibodies undetectable by chemiluminescent enzyme immunoassay require extended antigen-antibody reaction time for detection.
    Mai Y, Ujiie H, Higashi T, Yamagami J, Iwata H, Shimizu H
    Br J Dermatol 180: 215-216, 2019.
  • Linear immunoglobulin A/immunoglobulin G bullous dermatosis with autoantibodies to LAD-1 and laminin-gamma1.
    Matsudate Y, Yamasaki K, Ujiie H, Iwata H, Kubo Y
    Clin Exp Dermatol 44: e44-e46, 2019.
  • Cultured Epidermal Autografts from Clinically Revertant Skin as a Potential Wound Treatment for Recessive Dystrophic Epidermolysis Bullosa.
    Matsumura W, Fujita Y, Shinkuma S, Suzuki S, Yokoshiki S, Goto H, Hayashi H, Ono K, Inoie M, Takashima S, Nakayama C, Nomura T, Nakamura H, Abe R, Sato N, Shimizu H
    J Invest Dermatol 139: 2115-2124.e11, 2019.
  • Erythema multiforme-like hypersensitivity reaction to infliximab: an atypical and refractory case.
    Mizukami T, Fujita Y, Mai S, Miyazawa H, Miyauchi T, Muramatsu K, Katsurada T, Kobayashi H, Shimizu H
    Eur J Dermatol 29: 334-336, 2019.
  • Dermoscopic features of genital pigmented Bowen’s disease: Report of a case and review of the published work.
    Narahira A, Yanagi T, Kitamura S, Hata H, Shimizu H
    J Dermatol 46: e390-e391, 2019.
  • Congenital nevi with hypomelanosis and fine scales.
    Natsuga K, Oiso N, Kurokawa I, Tsubura A, Nakamura H, Maya Y, Nishie W, Kawada A, Shimizu H
    Eur J Dermatol 29: 45-48, 2019.
  • Image Gallery: Multiple localized lipoatrophy in recessive dystrophic epidermolysis bullosa.
    Nohara T, Fujita Y, Takashima S, Natsuga K, Shimizu H
    Br J Dermatol 180: e64, 2019.
  • Loss-of-function mutation in DSG1 underlies focal palmoplantar keratoderma.
    Nomura T, Takeda M, Peh JT, Miyauchi T, Suzuki S, Fujita Y, Uesugi T, Shimizu H
    J Eur Acad Dermatol Venereol 33: e137-e138, 2019.
  • Refractory oral ulcers in eosinophilic granulomatosis with polyangiitis.
    Otsuka T, Iwata H, Kosumi H, Muramatsu K, Ito T, Tsujiwaki M, Fujita Y, Kamaguchi M, Kitagawa Y, Shimizu H
    J Dermatol 46: e377-e378, 2019.
  • Mutant Lef1 controls Gata6 in sebaceous gland development and cancer.
    Oulès B, Rognoni E, Hoste E, Goss G, Fiehler R, Natsuga K, Quist S, Mentink R, Donati G, Watt FM
    EMBO J 38: e100526, 2019.
  • A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid.
    Schauer F, Kern JS, Virtic O, Technau-Hafsi K, Meiss F, Thoma K, Athanasiou I, Sitaru C, Di Zenzo G, Izumi K, Nishie W, Shimizu H, Bruckner-Tuderman L, Kiritsi D
    Br J Dermatol 180: 231-232, 2019.
  • Disseminated Mycobacterium intracellulare infection that led to recognition of idiopathic CD4(+) lymphocytopenia.
    Shimizu S, Takashima Y, Maya Y, Kodama F, Yokozeki M, Tomizawa K, Muramatsu K, Ujiie H, Shimizu H, Moriuchi R
    J Dtsch Dermatol Ges 17: 1066-1068, 2019.
  • Electron Microscopic and Immunohistochemical Findings of the Epidermal Basement Membrane in Two Families with Nail-patella Syndrome.
    Shinkuma S, Nakamura H, Maehara M, Takashima S, Nomura T, Fujita Y, Hasegawa S, Sato-Matsumura KC, Abe R, Shimizu H
    Acta Derm Venereol 99: 1110-1115, 2019.
  • Case of autoimmune intraepidermal and subepidermal blistering disease in which autoantibodies to Dsg1 and BP230 coexist.
    Sugai T, Ujiie H, Nakamura H, Kikuchi K, Iwata H, Shimizu H
    J Dermatol 46: e215-e216, 2019.
  • Somatic recombination underlies frequent revertant mosaicism in loricrin keratoderma.
    Suzuki S, Nomura T, Miyauchi T, Takeda M, Fujita Y, Nishie W, Akiyama M, Ishida-Yamamoto A, Shimizu H
    Life Sci Alliance 2: e201800284, 2019.
  • Ocular erythema nodosum.
    Takashima S, Ota M
    BMJ 366: l4899, 2019.
  • Petechial rash with parvovirus infection.
    Takashima S, Ota M
    BMJ 367: l5723, 2019.
  • Efficient Gene Reframing Therapy for Recessive Dystrophic Epidermolysis Bullosa with CRISPR/Cas9.
    Takashima S, Shinkuma S, Fujita Y, Nomura T, Ujiie H, Natsuga K, Iwata H, Nakamura H, Vorobyev A, Abe R, Shimizu H
    J Invest Dermatol 139: 1711-1721.e4, 2019.
  • A rare case of metastatic skin tumors originating from the sarcomatous component of lung carcinosarcoma.
    Takashima Y, Moriuchi R, Shirato T, Shimizu S
    Indian J Dermatol Venereol Leprol 85: 201-203, 2019.
  • Bullous pemphigoid IgG induces cell dysfunction and enhances the motility of epidermal keratinocytes via Rac1/proteasome activation.
    Tie D, Da X, Natsuga K, Yamada N, Yamamoto O, Morita E
    Front Immunol 10: 200, 2019.
  • BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer’s Disease than in Bullous Pemphigoid.
    Tuusa J, Lindgren O, Tertsunen HM, Nishie W, Kokkonen N, Huilaja L, Izumi K, Herukka SK, Miettunen J, Shimizu H, Remes AM, Tasanen K
    J Invest Dermatol 139: 293-299, 2019.
  • Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita).
    Ujiie H, Iwata H, Yamagami J, Nakama T, Aoyama Y, Ikeda S, Ishii N, Iwatsuki K, Kurosawa M, Sawamura D, Tanikawa A, Tsuruta D, Nishie W, Fujimoto W, Amagai M, Shimizu H
    J Dermatol 46: 1102-1135, 2019.
  • Immune Reaction to Type XVII Collagen Induces Intramolecular and Intermolecular Epitope Spreading in Experimental Bullous Pemphigoid Models.
    Ujiie H, Yoshimoto N, Natsuga K, Muramatsu K, Iwata H, Nishie W, Shimizu H
    Front Immunol 10: 1410, 2019.
  • Clinical and immunological features of pemphigus relapse.
    Ujiie I, Ujiie H, Iwata H, Shimizu H
    Br J Dermatol 180: 1498-1505, 2019.
  • The expression of cell adhesion molecule 1 and its splicing variants in Sezary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M, Morizane S, Hamada T, Miyake T, Sugaya M, Iwata H, Fujii K, Haramoto-Shiratsuki R, Nakagawa Y, Miura M, Ohshima K, Morishita K, Takahashi T, Imada M, Okada K, Uehara J, Sowa-Osako J, Iwatsuki K
    J Dermatol 46: 967-977, 2019.
  • Severe septic vasculitis preceding thoracic empyema: staphylococcus aureus enterotoxin deposition in vessel walls as a possible pathomechanism.
    Yamaguchi Y, Fujita Y, Ikeda T, Mai Y, Miyazawa H, Matsumura W, Nomura T, Shimizu H
    Acta Derm Venereol 99: 464-465, 2019.
  • CDK16/PCTK1/PCTAIRE1 is highly expressed in melanomas but not in melanocytic nevi or sarcomas.
    Yanagi T, Imafuku K, Kitamura S, Hata H, Shimizu H
    J Dermatol 46: 634-636, 2019.
  • Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
    Zheng M, Ujiie H, Iwata H, Muramatsu K, Yoshimoto N, Ito T, Ujiie I, Shimizu S, Sato-Matsumura KC, Shimizu H
    J Eur Acad Dermatol Venereol 33: 595-600, 2019.

日本語論文

  • ソラフェニブ投与中に下肢に生じた壊疽性膿皮症様皮膚障害の1例.
    羽賀直哉, 保科大地, 古屋和彦, 外丸詩野, 笹木有佑
    皮膚科の臨床 61: 1991-1994, 2019.
  • DPP-4阻害薬中止で自己抗体価が下がった天疱瘡2例と類天疱瘡1例.
    角田孝彦, 佐藤文子, 五十嵐雅彦, 石井文人, 橋本隆, 泉健太郎, 西江渉
    山形市立病院済生館医学雑誌 44: 90-94, 2019.
  • 水疱性類天疱瘡と糖尿病、DPP-4阻害薬との関連性 一施設における検討.
    原田泰枝, 藤山幹子, 松本圭子, 泉健太郎, 西江渉, 佐山浩二
    西日本皮膚科 81: 418-423, 2019.
  • Helicobacter cinaediによる蜂窩織炎の1例.
    高島有香, 守内玲寧, 白戸貴久, 永坂敦, 清水聡子
    臨床皮膚科 73: 829-833, 2019.
  • 【臀部の皮膚疾患】臨床例 急激な経過をたどった,CD56陽性・ALK陰性全身型未分化大細胞リンパ腫.
    高島有香, 守内玲寧, 堀田萌子, 山口圭介, 山本聡, 清水聡子
    皮膚病診療 41: 169-172, 2019.
  • 【水疱症・膿疱症】抗BP180NC16a抗体陽性のDPP-4阻害薬による水疱性類天疱瘡の3例.
    佐々木仁, 矢口順子, 佐藤文子, 角田孝彦, 五十嵐雅彦, 泉健太郎, 西江渉, 橋本隆
    皮膚科の臨床 61: 159-163, 2019.
  • 第Xa因子阻害薬アピキサバンが著効したリベド様血管症.
    山口泰之, 平田悠
    皮膚病診療 41: 673-676, 2019.
  • 中型の先天性色素性母斑を母地として成人に生じたproliferative noduleの1例.
    水上卓哉, 藤田靖幸, 真屋由佳, 川嶋邦裕, 辻隆裕, 新井栄一, 本間光一, 清水聡子
    市立札幌病院医誌 79: 31-37, 2019.
  • 水痘ワクチン由来帯状疱疹.
    川村拓也, 大田光仁
    Visual Dermatology 18: 928-929, 2019.
  • ペムブロリズマブの乾癬様皮膚障害の1例.
    白戸貴久, 宮澤元, 佐藤英嗣
    帯広厚生病院医誌 21: 22-25, 2019.
  • 血管拡張性肉芽腫に類似した臨床像を呈したAneurysmal Fibrous Histiocytomaの1例.
    白戸貴久, 平田悠, 菊池慶介, 熊切正信, 佐藤英嗣
    皮膚科の臨床 61: 1187-1190, 2019.
  • 重症汎発性接合部型表皮水疱症の1家系.
    平岡美樹子, 今門純久, 夏賀健, 秋山真志, 澤村大輔, 清水宏
    日本皮膚科学会雑誌 129: 2525-2532, 2019.
  • リポフスチンはアポクリン汗嚢腫の色調に関連する.
    北村真也
    皮膚病診療 41: 1098-1102, 2019.
  • 著明な色素沈着を伴った脛骨前粘液水腫.
    堀田萌子, 野村友希子
    KKR札幌医療センター医学雑誌 16: 54-58, 2019.
  • 直腸瘻を伴う仙骨部褥瘡の1例-放射線晩期障害の影響.
    野村友希子, 月永一郎, 大渕佳祐, 武田圭佐
    臨床皮膚科 73: 113-116, 2019.
  • 発症から診断までに10年以上が経過した粘膜類天疱瘡の1例.
    鈴木丈雄, 新熊悟, 荻根沢真帆子, 会沢敦子, 高橋奈央, 泉健太郎, 氏家英之, 西江渉, 阿部理一郎
    臨床皮膚科 73: 813-817, 2019.
  • 小児線状強皮症に対してシクロスポリン内服が有効であった2例.
    眞井翔子, 藤田靖幸, 夏賀健, 西江渉, 小野寺智洋, 岡敏明, 清水宏
    皮膚科の臨床 61: 1797-1802, 2019.

総説

  • Current Clinical Trials in Pemphigus and Pemphigoid.
    Izumi K, Bieber K, Ludwig RJ
    Front Immunol 10: 978, 2019.
  • Life before and beyond blistering: The role of collagen XVII in epidermal physiology.
    Natsuga K, Watanabe M, Nishie W, Shimizu H
    Exp Dermatol 28: 1135-1141, 2019.
  • Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
    Nishie W
    Immunol Med 42: 22-28, 2019.
  • Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K, Varpuluoma O, Nishie W
    Front Immunol 10: 1238, 2019.
  • Regulatory T cells in autoimmune skin diseases.
    Ujiie H
    Exp Dermatol 28: 642-646, 2019.
  • 自己免疫性水疱症: 診断・病態の最新の進歩.
    夏賀健
    日本皮膚科学会雑誌 129: 2749-2754, 2019.
  • 【内科医のための皮膚疾患アトラス-日常診療における部位別皮疹の診かた-】(Part2)症例 皮疹(皮膚所見)からの診断と治療へのアプローチ<部位別> 全身 全身の水ぶくれ.
    夏賀健
    診断と治療 107: 324-325, 2019.
  • 日本皮膚科学会ガイドライン 皮膚悪性腫瘍ガイドライン第3版 メラノーマ診療ガイドライン2019.
    中村泰大, 浅井純, 井垣浩, 猪爪隆史, 並川健二郎, 林礼人, 福島聡, 藤村卓, 伊東孝通, 今福惠輔, 田中亮多, 寺本由紀子, 皆川茜, 宮川卓也, 宮下梓, 和田誠, 古賀弘志, 菅谷誠, 公益社団法人日本皮膚科学会, 一般社団法人日本皮膚悪性腫瘍学会, 皮膚悪性腫瘍診療ガイドライン改訂委員会
    日本皮膚科学会雑誌 129: 1759-1843, 2019.
  • 表皮水疱症の症状と治療.
    高島翔太, 藤田靖幸
    難病と在宅ケア 25: 29-35, 2019.
  • 自己免疫性水疱症の診断の最前線.
    氏家英之
    検査と技術 48: 10-13, 2019.
  • 糖尿病と皮膚疾患、特にDPP-4阻害薬と水疱性類天疱瘡の関連.
    氏家英之
    DM Ensemble 8: 42-45, 2019.
  • DPP-4阻害薬関連類天疱瘡:通常の水疱性類天疱瘡と比べた特徴.
    西江渉
    病理と臨床 37: 1193-1200, 2019.
  • 【Paget病のすべて】(Part1) Paget病の診断と治療 乳房外Paget病剖検例.
    前田拓哉, 吉野公二
    Visual Dermatology 18: 260-265, 2019.
  • 全身のかゆい皮疹: アトピー性皮膚炎.
    乃村俊史
    診断と治療 107: 311-312, 2019.
  • 脂漏性皮膚炎.
    保科大地
    日本医事新報: 4955: 45, 2019.
  • アトピー性皮膚炎.
    乃村俊史
    日本医事新報 4964: 45, 2019.
  • ジベルバラ色粃糠疹.
    藤田靖幸
    日本医事新報 4975: 41, 2019.
  • 鶏眼(うおのめ)・胼胝腫(たこ).
    夏賀健
    日本医事新報 4976: 48, 2019.

著書・その他

  • 表皮水疱症の症状と治療.
    高島翔太, 藤田靖幸
    難病と在宅ケア. 東京: 日本プランニングセンター. 2019. pp 29-35.
  • 高齢者の自己免疫性水疱症をとらえる~水疱性類天疱瘡.
    氏家英之
    高齢者皮膚診療のコツとピットフォール. 東京: 南江堂. 2019. pp 91-94.
  • ステロイドが減量できない天疱瘡.
    氏家英之
    皮膚科トラブル対応テキスト. 東京: 文光堂. 2019. pp 148-149.
  • Q32. 糖尿病治療薬であるDPP-4阻害薬と類天疱瘡の関係について教えてください.また,薬剤を使用中に類天疱瘡を発症した際の対処法について教えてください.
    氏家英之
    プラクティスセレクション 糖尿病の療養指導 Q&A vol.2. 東京: 医歯薬出版株式会社. 2019. pp 104-106.
  • 「類天疱瘡(後天性表皮水疱症を含む)診療ガイドライン」の検証.
    氏家英之
    皮膚疾患最新の治療2019-2020. 東京: 南江堂. 2019. pp 9-13.
  • 魚鱗癬.
    乃村俊史
    皮膚疾患最新の治療2019-2020. 東京: 南江堂. 2019. pp 145-146.
  • 糖尿病性潰瘍.
    今福恵輔
    私の治療 2019-2020年度版. 日本医事新報: e14-23, 2019.
  • 褥瘡.
    今福恵輔私の治療 2019-2020年度版. 日本医事新報: e14-24, 2019.